HEK293 cells were transiently cotransfected having a SARS\CoV\2?spike\encoding?and a GFP\reporter plasmid. We provide compelling evidence that the third vaccination with BNT162b2 increases the amount of neutralizing serum antibodies against Delta and Omicron variants, albeit to a lower degree when compared to the parental Wuhan strain. Therefore, a third vaccination is definitely warranted to increase titers of protecting serum antibodies, especially in the case of the Omicron variant. We also found that most clinically approved and normally potent restorative antibodies against the Delta variant failed to recognize and neutralize the Omicron variant. In contrast, some antibodies under preclinical development potentially neutralized the Omicron variant. Our studies also support using a circulation cytometry\centered antibody binding assay to rapidly monitor therapeutic candidates and serum titers against growing SARS\CoV\2 variants. Keywords: boost immunization, coronavirus, COVID\19, neutralizing antibody, SARS\CoV\2, vaccination Using pseudotype neutralization and circulation cytometry\centered spike protein binding assays, Schulz and colleagues display that a boost with BNT162b2 improved neutralizing antibody reactions against Omicron, albeit less than against the Wuhan strain and the Delta variant. In contrast, most clinically authorized monoclonal antibodies failed to identify the Omicron variant. Intro Coronavirus disease 2019 (COVID\19) caused by the severe acute T respiratory syndrome coronavirus 2 (SARS\CoV\2) is an infectious disease with variable outcomes. SARS\CoV\2 illness, as well as mRNA\, DNA vector\, and protein\centered vaccinations, induce neutralizing antibodies and the formation of antigen\specific T cells for durable cellular and humoral immune memory space [1, 2]. Effective vaccines and several potent computer virus\neutralizing antibodies have been a game changer in the fight against this devastating COVID\19 pandemic [3, 4]. The RNA\centered vaccine from BioNTech (BNT162b2) and the two\antibody cocktail Ronapreve (consisting of from Regeneron were the 1st that obtained authorized usage in the European Union (EU) from your European Medicines Agency (EMA) in 2020 for safety against and treatment of early COVID\19 symptoms, respectively [5]. Furthermore, EMA just authorized the use of a fifth vaccine, the first protein\centered vaccine Nuvaxovid [6], and the anti\CoV\2 antibodies Xevudy (Sotrovimab from VirTechnology/GSK) and Regkirona (Regdanvimab from Celltrion) for COVID\19 treatment [7]. In addition, the two\antibody cocktail Evusheld (Tixagevimab and Cilgavimab from AstraZeneca) is currently under rolling review [7]. Computer virus variants of concern have acquired Arry-380 analog mutations that switch the computer virus infectivity and pathogenicity and enable the computer virus variant to escape at least in part from vaccine\induced antibody reactions and currently authorized therapeutic antibodies. For example, sera from two times\vaccinated individuals and therapeutic candidate monoclonal antibodies showed a reduced neutralizing activity against the Delta variant [8, 9]. Here, we make use of a circulation cytometry\centered antibody binding assay with SARS\CoV\2 spike\transfected HEK293 cells and a vesicular stomatitis computer virus (VSV)\centered pseudotype neutralization assay to analyze whether a third immunization, that is, the second boost vaccination, can increase the serum activity of neutralizing antibodies against the recently emerged and rapidly distributing SARS\CoV\2 Omicron variant [10]. Results and conversation Enhanced neutralization of SARS\CoV\2 Omicron variant by improving double\vaccinated individuals To test our hypothesis that the third dose of BNT162b2 augments the Omicron spike\binding and \neutralizing antibody response, we recruited individuals who have received a boost vaccination between 4 to 9 weeks after their second vaccination and collected sera samples before and 10 to 78 days after their third dose (Supporting information Table S1). To quickly determine whether the antibody binding capacity to the Omicron spike protein increases after a boost, we used a circulation cytometry\centered IgG\binding assay with HEK293 cells that were transiently transfected with the spike membrane protein of the Wuhan\Hu\1 strain and the SARS\CoV\2 Delta and Omicron variants (Fig.?1A and B). The surface abundance of the spike proteins was similar among the three variants, as shown by a similar binding of the Arry-380 analog CVR12 antibody that recognizes a shared conserved epitope (Fig.?2A). The slightly lower surface large quantity observed for the Wuhan spike protein could be explained from the absence of the D614G mutation reported to increase the membrane spike protein stability [11]. Open in a separate window Number 1 Booster immunization of double\vaccinated individuals raises Omicron spike protein\binding and \neutralizing antibodies. (A) Schematic overview of the SARS\CoV\2 spike proteins. The amino acid Arry-380 analog changes in the spike proteins of variants of concern (VoC) compared to the research genome of the Wuhan\Hu\1 strain (GenBank accession no. “type”:”entrez-nucleotide”,”attrs”:”text”:”MN908947″,”term_id”:”1798172431″,”term_text”:”MN908947″MN908947) are demonstrated for the Delta and Omicron variants. The S1/S2 and S2 cleavage sites are indicated by black bars. NTD, N\terminal website; RBD, receptor\binding website; RBM, receptor\binding motif; FP, fusion peptide; HR, heptad repeat, TM, transmembrane website. (B) Circulation cytometry\centered assay to determine antibody binding to SARS\CoV\2 spike proteins. HEK293 cells were transiently cotransfected having a SARS\CoV\2?spike\encoding?and a GFP\reporter plasmid. Arry-380 analog Transfected cells were stained with serum samples from vaccinated individuals (1:100 dilutions) followed by staining with AF647\conjugated goat antibodies against human being IgG. Cells were gated, as depicted in Assisting information Number S2. Assays were performed.